Hoth Therapeutics Files 8-K on Agreements and Equity Sales

Ticker: HOTH · Form: 8-K · Filed: 2026-04-02T16:18:12-04:00

Sentiment: neutral

Topics: financing, securities-offering, material-agreement

Related Tickers: HOTH

TL;DR

HOTH filed an 8-K detailing new agreements and equity sales, potentially a financing round.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting on a material definitive agreement and unregistered sales of equity securities. The filing includes exhibits such as a Securities Purchase Agreement and forms of warrants, indicating potential financing or strategic transactions. The company also issued press releases on April 1 and April 2, 2026, related to these events.

Why It Matters

This filing signals potential new financing or strategic partnerships for Hoth Therapeutics, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.

Key Players & Entities

Hoth Therapeutics, Inc. (company) — Filer of the 8-K report
0001711786 (company) — CIK number for Hoth Therapeutics, Inc.
0001213900-26-039363 (company) — SEC Accession Number for the filing
April 2, 2026 (date) — Filing date of the 8-K
April 1, 2026 (date) — Date of one of the press releases

FAQ

What type of material definitive agreement did Hoth Therapeutics enter into?

The filing indicates a 'Securities Purchase Agreement' (Exhibit 10.1) as a material definitive agreement.

What are the key exhibits attached to this 8-K filing?

Key exhibits include the Form of Warrant (EX-4.1), Form of Placement Agent Warrant (EX-4.2), Opinion of Sheppard, Mullin, Richter & Hampton LLP (EX-5.1), Form of Securities Purchase Agreement (EX-10.1), and Press Releases dated April 1 and April 2, 2026 (EX-99.1 and EX-99.2).

What items of the 8-K form are being reported on?

The filing reports on Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).

When was this 8-K filing accepted by the SEC?

The filing was accepted on April 2, 2026, at 16:18:12.

What is the business address of Hoth Therapeutics, Inc. according to this filing?

The business address listed is 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036.

From the Filing

EDGAR Filing Documents for 0001213900-26-039363 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001213900-26-039363 Filing Date 2026-04-02 Accepted 2026-04-02 16:18:12 Documents 18 Period of Report 2026-04-01 Items Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 CURRENT REPORT ea0284778-8k_hoth.htm iXBRL 8-K 38454 2 FORM OF WARRANT ea028477801ex4-1.htm EX-4.1 107499 3 FORM OF PLACEMENT AGENT WARRANT ea028477801ex4-2.htm EX-4.2 99638 4 OPINION OF SHEPPARD, MULLIN, RICHTER & HAMPTON LLP ea028477801ex5-1.htm EX-5.1 13788 5 FORM OF SECURITIES PURCHASE AGREEMENT ea028477801ex10-1.htm EX-10.1 246459 6 PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED APRIL 1, 2026 ea028477801ex99-1.htm EX-99.1 13376 7 PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED APRIL 2, 2026 ea028477801ex99-2.htm EX-99.2 12699 8 GRAPHIC ea028477801_ex5-1img1.jpg GRAPHIC 3355 Complete submission text file 0001213900-26-039363.txt 835881 Data Files Seq Description Document Type Size 9 XBRL SCHEMA FILE hoth-20260401.xsd EX-101.SCH 3038 10 XBRL LABEL FILE hoth-20260401_lab.xml EX-101.LAB 34239 11 XBRL PRESENTATION FILE hoth-20260401_pre.xml EX-101.PRE 22374 22 EXTRACTED XBRL INSTANCE DOCUMENT ea0284778-8k_hoth_htm.xml XML 3318 Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997 Hoth Therapeutics, Inc. (Filer) CIK : 0001711786 (see all company filings) EIN. : 821553794 | State of Incorp.: NV | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 26833824 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)